focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.65
Bid: 5.65
Ask: 5.90
Change: 0.72 (14.60%)
Spread: 0.25 (4.425%)
Open: 4.78
High: 5.65
Low: 4.78
Prev. Close: 4.93
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Technology Update

6 Jun 2017 07:00

RNS Number : 2009H
Plant Health Care PLC
06 June 2017
 

6 June 2017

Plant Health Care plc(the "Company" ", "PHC" or "Plant Health Care")New Technology Update

Plant Health Care (AIM: PHC), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update in relation to its New Technology business.

Highlights

- Evaluation of Innatus 3G continues to expand. The four major industry partners have increased the scale of their 2017 trials. Three other companies have signed evaluation agreements and are conducting field trials.

- A total of eight agreements have also now been signed concerning T-Rex 3G and Y-Max-3G.

- Strong progress continues within Plant Health Care on its capability to make, formulate and register PREtec peptides.

- The Company remains on track to deliver a revenue-generating licence by the end of 2017 and the first competitive licensing process in early 2018.

 

Innatus 3G

Four of the top six agrochemicals companies have been evaluating Innatus 3G since 2015. They are focused on three core agricultural benefits - yield increase, disease and nematode protection and drought resistance - mainly in the largest commercial crops corn (maize) and soybean. Building on their 2016 results, all are running trials of lead peptides from this platform in 2017.

By early 2017, three other companies had signed agreements to evaluate Innatus 3G. Their field trials, in other smaller crops, are underway in Europe and South America.

In recent weeks several partners have approached PHC with plans to expand their 2017 trials further. Of particular interest is the control of Asian Soybean Rust, a fungal disease which is a major threat to the soybean crop in Brazil. This disease has developed resistance to most conventional fungicides. Innatus 3G peptides work very differently, and when sprayed in mixtures with standard fungicides, they have shown significantly improved disease control in PHC's trials. This has the potential to increase the effectiveness and extend the commercial life of those established products.

T-Rex 3G and Y-Max 3G

PHC's new technology platforms, T-Rex 3G and Y-Max 3G, were first presented to the industry in 2016. T-Rex 3G is a class of signal peptides optimised for nematode suppression, while Y-Max 3G peptides are biostimulants which increase yield.

A total of eight companies have so far signed up to evaluate one or both of these new platforms, including the majors who are evaluating Innatus 3G. Trials are in progress in three continents in a range of crops, with two lead peptides from each of T-Rex 3G and Y-Max 3G. The majors are focused mainly on corn and soybean, while others are working on a wider range of crops.

The Company continues to aim to secure the first revenue-generating licence of one of its PREtec technologies in 2017.

PHC's product development capability

Plant Health Care has increased its product development activity. This includes substantially expanding its own 2017 field trials and contract testing programme. But because partners' evaluations of PREtec peptides are on a much larger scale than in 2016, collectively they are spending many times more than the Company is.

Plant Health Care's work on the physical stability of peptides in formulations and their compatibility with agrochemicals continues to show promising results. We expect the most cost-effective means of peptide manufacture to be by fermentation, and laboratory scale production trials are on track. The first lead peptides produced by fermentation are being evaluated and will shortly be entering field trials.

 

Chris Richards, Executive Chairman & Interim CEO, said "Momentum continues to build. As we approach the expected 2018 date for licensing of first rights to Innatus 3G, partners are stepping up their evaluations. Our lead peptides from each platform are performing well in independent trials, carried out by our partners."

"It is a great vote of confidence in our proprietary technology. Every one of our initial partners is now testing one or both of T-Rex 3G and Y-Max 3G, alongside Innatus 3G. Our new partners are expanding the range of crops to which our products can bring benefits. This year, partners will spend much more than us on evaluating our proprietary technology."

"We are well positioned for the first licensing of our PREtec technology by the end of 2017, with competitive licensing of Innatus 3G to start in early 2018."

 

Enquiries:

Plant Health Care plc

Dr Chris Richards, Executive Chairman and Interim CEO

Tel: +44 (0) 18 3788 0083

Liberum Capital - Nomad and Broker

Clayton Bush / Chris Clarke

Tel: +44 (0) 20 3100 2000

Company website: www.planthealthcare.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESUGUWCQUPMGMA
Date   Source Headline
17th May 20077:01 amRNSBoard Change
14th May 20077:00 amRNSNotice of AGM
1st May 20073:25 pmRNSTotal Voting Rights
26th Apr 20079:23 amRNSAnnual Report and Accounts
19th Apr 20071:22 pmRNSDirector/PDMR Shareholding
18th Apr 20075:42 pmRNSDirector/PDMR Shareholding
16th Apr 20077:02 amRNSFinal Results
16th Apr 20077:02 amRNSSuccessful Trial Results
30th Mar 20074:54 pmRNSTotal Voting Rights
30th Mar 20074:51 pmRNSHolding(s) in Company
23rd Mar 20076:19 pmRNSHolding(s) in Company
13th Mar 20079:01 amRNSNotice of Results
5th Mar 20075:36 pmRNSExercise of Options
5th Mar 20075:20 pmRNSHolding(s) in Company
5th Mar 20078:04 amRNSHolding(s) in Company
1st Mar 20073:33 pmRNSTotal Voting Rights
1st Mar 20077:04 amRNSRe Acquisition
15th Feb 20079:04 amRNSPartnership
8th Feb 200712:13 pmRNSAdditional Listing
6th Feb 20075:52 pmRNSAdditional Listing
5th Feb 200710:19 amRNSHolding(s) in Company
2nd Feb 20078:40 amRNSHolding(s) in Company
31st Jan 20077:01 amRNSDirector/PDMR Shareholding
24th Jan 200712:01 pmRNSHolding(s) in Company
19th Jan 200712:24 pmRNSTotal Voting Rights
18th Jan 20076:06 pmRNSDirector/PDMR Shareholding
17th Jan 20077:01 amRNSMyconate Agreement
17th Jan 20077:01 amRNSTrading Statement
15th Jan 200710:42 amRNSMyconate Update
5th Jan 20079:01 amRNSExercise of Options
20th Dec 20064:14 pmRNSTotal Voting Rights
4th Dec 20067:00 amRNSAcquisition
14th Nov 20063:59 pmRNSAdditional Listing
13th Nov 20067:01 amRNSSupply Agreement & New Order
24th Oct 200610:52 amRNSHolding(s) in Company
16th Oct 20068:55 amRNSHolding(s) in Company
11th Oct 200610:34 amRNSHolding(s) in Company
29th Sep 200610:04 amRNSInterim Report
27th Sep 20061:43 pmRNSExercise of options
26th Sep 20067:02 amRNSInterim Results
26th Sep 20067:02 amRNSUpdated Myconate Release
13th Sep 20067:01 amRNSNotice of Results
1st Aug 20062:31 pmRNSAdditional Listing
16th Jun 20068:38 amRNSDirector/PDMR Shareholding
9th Jun 200611:31 amRNSAGM Statement
8th Jun 20061:15 pmRNSPress Speculation Re Pre Tect
1st Jun 20067:01 amRNSDistribution Agreement
23rd May 200611:23 amRNSHolding(s) in Company
19th May 200610:13 amRNSExercise of Warrants
12th May 20067:00 amRNSNew US Distributor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.